Stonepine Capital Management LLC trimmed its stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 73.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 663,405 shares of the biotechnology company's stock after selling 1,795,468 shares during the period. Aclaris Therapeutics comprises about 1.3% of Stonepine Capital Management LLC's investment portfolio, making the stock its 23rd largest position. Stonepine Capital Management LLC owned 0.93% of Aclaris Therapeutics worth $1,645,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently bought and sold shares of the company. Assenagon Asset Management S.A. increased its stake in shares of Aclaris Therapeutics by 113.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 397,362 shares of the biotechnology company's stock valued at $985,000 after buying an additional 211,585 shares in the last quarter. Peapod Lane Capital LLC acquired a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at $1,003,000. Charles Schwab Investment Management Inc. bought a new stake in shares of Aclaris Therapeutics during the fourth quarter valued at approximately $82,000. Raymond James Financial Inc. acquired a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $383,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Aclaris Therapeutics by 173.4% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 908,819 shares of the biotechnology company's stock valued at $2,254,000 after purchasing an additional 576,413 shares in the last quarter. 98.34% of the stock is currently owned by institutional investors.
Aclaris Therapeutics Stock Performance
ACRS traded down $0.06 during midday trading on Wednesday, reaching $1.29. 640,661 shares of the company were exchanged, compared to its average volume of 1,183,345. Aclaris Therapeutics, Inc. has a one year low of $0.95 and a one year high of $5.17. The stock has a market capitalization of $139.68 million, a P/E ratio of -2.48 and a beta of 0.42. The stock's 50-day simple moving average is $1.35 and its 200 day simple moving average is $2.22.
Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.07. Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%. On average, research analysts anticipate that Aclaris Therapeutics, Inc. will post -0.82 earnings per share for the current year.
Analyst Ratings Changes
A number of research analysts have commented on the company. Cantor Fitzgerald assumed coverage on Aclaris Therapeutics in a research report on Tuesday, March 18th. They issued an "overweight" rating on the stock. HC Wainwright reiterated a "buy" rating and issued a $16.00 price target (down previously from $20.00) on shares of Aclaris Therapeutics in a report on Wednesday, May 14th. Scotiabank dropped their price objective on Aclaris Therapeutics from $15.00 to $9.00 and set a "sector outperform" rating for the company in a report on Friday, May 9th. Finally, StockNews.com cut Aclaris Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, February 8th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $10.00.
Check Out Our Latest Research Report on Aclaris Therapeutics
Aclaris Therapeutics Profile
(
Free Report)
Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.
Read More
Before you consider Aclaris Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aclaris Therapeutics wasn't on the list.
While Aclaris Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
